Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Patients with type 2 diabetes who used a smartphone app for cognitive behavioral therapy showed a significant decrease in A1c levels.
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
2.
Annual whole-body, low-dose CT aids management of smoldering multiple myeloma
3.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
4.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
5.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
1.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
2.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
3.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
4.
Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge